Haemophilia A and B are hereditary haemorrhagic disorders characterised by deficiency or
dysfunction of coagulation protein factors VIII and IX, respectively. Recurrent joint and …

Of the various types of hemophilia, the most common of these lifelong bleeding disorders
are due to an inherited deficiency of factor VIII or factor IX (Table 1). The genes for these …

The dramatic hemorrhages, the effect of the disease on history through its presence in
Queen Victoria's descendants, and the devastating role of therapeutic concentrates in the …

The development of inhibitory antibodies to factor VIII is a serious complication of
hemophilia. FEIBA (factor VIII inhibitor-bypassing activity), an activated prothrombin complex …

Factor VIII (FVIII) replacement therapy is the foundation of treatment in hemophilia A and is
effective unless a patient develops an alloantibody (inhibitor) against exogenous FVIII …

Inhibitors in patients with hemophilia are a rare complication of a rare disease causing pain
and disability in patients and impairment to the quality of their lives. Recent advances in …

The revised UKHCDO factor (F) VIII/IX Inhibitor Guidelines (2000) are presented. A schema
is proposed for inhibitor surveillance, which varies according to the severity of the …

Acquired hemophilia A is a rare but severe autoimmune bleeding disorder. It is more
frequent in the elderly and results from the presence of autoantibodies directed against …

Background: Previous studies of the development of inhibitors and their impact on mortality
have been small. Objectives: To examine the development of inhibitors in people with …

Recombinant factor VIIa was initially developed for the treatment of hemorrhagic episodes in
hemophilic patients with inhibitors to factors VIII and IX. After its introduction, it has also been …